These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-000362-12 A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis bad-data
Not reported 2004-002090-23 A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia. 2005-10-17 due-trials
Listed as ongoing, but also has a completion date 2005-001000-39 STUDY OF PITAVASTATIN 2 MG vs. ATORVASTATIN 10 MG AND PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA 2006-11-08 bad-data
Not reported 2005-001033-15 STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG FOLLOWING UP-TITRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA 2006-09-29 due-trials
Listed as ongoing, but also has a completion date 2005-001037-15 STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE 2006-10-02 bad-data
Listed as ongoing, but also has a completion date 2005-001038-34 STUDY OF PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEMIA 2007-09-12 bad-data
Listed as ongoing, but also has a completion date 2005-001039-31 STUDY OF PITAVASTATIN 1 MG vs. PRAVASTATIN 10 MG, PITAVASTATIN 2 MG vs. PRAVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. PRAVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN ELDERLY PATIENTS WITH PRIMARY HYPERCHO... 2006-05-12 bad-data
Listed as ongoing, but also has a completion date 2005-001112-41 OPEN-LABEL, LONG TERM 1 YEAR EXTENSION STUDY OF PITAVASTATIN 4MG QD IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA 2007-11-26 bad-data
Listed as ongoing, but also has a completion date 2005-005980-27 OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA 2007-12-19 bad-data
Listed as ongoing, but also has a completion date 2005-005981-35 DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS SIMVASTATIN (40 MG AND 80 MG), WITH A SINGLE-BLIND EXTENSION OF TREATMENT, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPID... 2007-08-07 bad-data
Listed as ongoing, but also has a completion date 2005-006041-16 Double-blind follow on study of pitavastatin (4 mg)versus atorvastatin (20 and 40 mg), with a single-blind extension of treatment, in patients with type II diabetes mellitus and combined dyslipidemia 2008-04-29 bad-data
Reported results 2011-004964-32 A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 2013-06-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-004983-32 A 52-Week Open-Label Extension and Safety Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood, P/266/2011, P/267/2011, P/268/2011 2014-06-10 bad-data
Reported results 2013-001517-32 A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels 2014-09-23 due-trials
Ongoing 2015-003511-37 A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double­Blind, 12-Week Study With a 40-Week, Active-Controlled, Double­Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pat... not-yet-due
Ongoing 2016-001518-39 A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patie... not-yet-due
Ongoing 2016-003818-26 Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT) not-yet-due